<DOC>
	<DOCNO>NCT00433966</DOCNO>
	<brief_summary>The primary objective trial : 1 . To establish safety efficacy use bivalirudin ( + bail-out GP IIb/IIIa inhibitor ) compare use unfractionated heparin + GP IIb/IIIa inhibitor patient acute myocardial infarction undergo primary angioplasty strategy . 2 . To establish safety efficacy slow rate release paclitaxel-eluting TAXUS™ stent compare otherwise identical uncoated bare metal EXPRESS2™ stent .</brief_summary>
	<brief_title>Harmonizing Outcomes With Revascularization Stents Acute Myocardial Infarction</brief_title>
	<detailed_description>Prospective , 2 x 2 factorial single blind , randomize , multi-center trial 3400 patient enrol 200 center . Patients randomize 1:1 emergency room ) anticoagulation unfractionated heparin plus routine GP IIb/IIIa inhibition vs. b ) bivalirudin bail-out GP IIb/IIIa inhibition . Following angiography , patient lesion eligible stenting undergo second randomization ( 3:1 ) stent implantation either ) slow rate-release paclitaxel-eluting stent ( TAXUS™ ) b ) otherwise identical uncoated bare metal stent ( EXPRESS2™ ) .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Bivalirudin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<mesh_term>Hirudins</mesh_term>
	<criteria>Must clinical symptom consistent AMI ( e.g. , angina anginal equivalent ) last &gt; 20 minute &lt; 12 hour duration ; STsegment elevation &gt; 1 mm &gt; 2 contiguous lead , ( presumably new ) leave bundle branch block , true posterior MI ST depression &gt; 1 mm &gt; 2 contiguous anterior lead ; The patient guardian agree study protocol schedule clinical angiographic followup , provide informed , write consent . The patient know hypersensitivity contraindication follow medication : Heparin , pork pork product Both abciximab eptifibatide Aspirin Both Clopidogrel Ticlopidine Bivalirudin Paclitaxel Taxol The polymer component TAXUS™ stent ( SIBS ) Stainless steel and/or Contrast medium ; Prior administration thrombolytic therapy , bivalirudin , GP IIb/IIIa inhibitor , low molecular weight heparin fondaparinux admission . Patients receive prior unfractionated heparin may enrol , treat per randomization ; Current use coumadin ; Systemic ( intravenous ) Paclitaxel Taxol use within 12 month ; Female childbearing potential , unless recent pregnancy test negative , possibly plan become pregnant time enrollment study ; History bleed diathesis know coagulopathy ( include heparininduced thrombocytopenia ) , refuse blood transfusion ; History intracerebral mass , aneurysm , arteriovenous malformation , hemorrhagic stroke ; Stroke transient ischemic attack within past 6 month , permanent residual neurologic defect ; Gastrointestinal genitourinary bleeding within last 2 month , major surgery within six week ; Recent history know current platelet count &lt; 100,000 cells/mm3 Hgb &lt; 10 g/dL ; Extensive peripheral vascular disease , emergent angiography intervention opinion investigator likely difficult complicate ; An elective surgical procedure plan would necessitate interruption thienopyridines first six month post enrollment ; Noncardiac comorbid condition present life expectancy &lt; 1 year may result protocol noncompliance ; Patients actively participate another drug device investigational study , complete primary endpoint followup period ; Previous enrollment trial ; Patients underwent coronary stent implantation within past 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Myocardial Infarction</keyword>
	<keyword>Angioplasty</keyword>
	<keyword>Myocardial Ischemia</keyword>
	<keyword>Myocardial Reperfusion</keyword>
	<keyword>Stents</keyword>
	<keyword>Heart Disease</keyword>
</DOC>